| Quarterly Financials | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 1,345 | 1,612 | 1,709 | 2,229 | 1,574 | 1,777 | 1,814 | 2,196 | 1,802 | 1,980 | 2,034 | 2,591 | 1,993 | 2,320 | 2,233 | 2,812 | 2,031 |
| Expenses | 1,197 | 1,381 | 1,314 | 1,733 | 1,465 | 1,554 | 1,629 | 1,812 | 1,617 | 1,646 | 1,723 | 2,053 | 1,747 | 1,900 | 1,867 | 2,193 | 1,827 |
| EBITDA | 148 | 231 | 395 | 495 | 109 | 223 | 185 | 384 | 185 | 334 | 312 | 538 | 246 | 420 | 367 | 619 | 204 |
| Operating Profit % | 9 % | 12 % | 15 % | 19 % | 1 % | 10 % | 5 % | 16 % | 8 % | 14 % | 12 % | 20 % | 10 % | 15 % | 15 % | 20 % | 6 % |
| Depreciation | 136 | 138 | 147 | 165 | 162 | 166 | 164 | 184 | 174 | 185 | 186 | 196 | 185 | 192 | 197 | 243 | 197 |
| Interest | 42 | 49 | 50 | 57 | 62 | 83 | 95 | 104 | 119 | 110 | 106 | 114 | 107 | 108 | 103 | 104 | 86 |
| Profit Before Tax | -30 | 44 | 198 | 273 | -115 | -26 | -74 | 95 | -107 | 40 | 19 | 228 | -45 | 120 | 67 | 273 | -79 |
| Tax | -2 | 7 | 35 | 69 | -6 | 11 | 17 | 45 | -9 | 35 | 9 | 126 | 44 | 98 | 63 | 119 | 3 |
| Net Profit | -28 | 37 | 163 | 204 | -109 | -37 | -90 | 50 | -99 | 5 | 10 | 101 | -89 | 23 | 4 | 154 | -82 |
| EPS in ₹ | 0.00 | 0.31 | 1.38 | 1.72 | -0.92 | -0.31 | -0.76 | 0.42 | -0.83 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.62 |
Piramal Pharma
Piramal Pharma
187.73
-7.47
(-3.83%)
Market Cap
24,954.00 Cr
EPS
0.69
PE Ratio
288.85
Dividend Yield
0.07 %
Industry
Healthcare52 Week High
307.90
52 Week Low
181.73
PB Ratio
3.07
Debt to Equity
0.60
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from9 analysts
Company News
View All News
Piramal Pharma and NewAmsterdam Pharma have announced a joint investment to improve oral solid dosage manufacturing capabilities. The investment will create over 20 new jobs at the Sellersville site as part of the capacity enhancement initiative.
A subsidiary of Piramal Pharma has made an investment of $190.3 million in PPL Pharma Inc. The investment represents a significant capital deployment by the pharmaceutical company's subsidiary unit.
Piramal Pharma Limited experienced a fire incident at a third-party warehouse in Annaram, Telangana during the night of August 6, 2025. The fire affected inventory valued at Rs 45 crores, which is covered by insurance and the claims process has begun. The fire is largely under control and emergency response actions were undertaken promptly. The cause remains under investigation. The company is working with suppliers to restore inventory and with customers to resume supplies.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
11.25 %
Net Income Growth
411.80 %
Cash Flow Change
-11.17 %
ROE
386.96 %
ROCE
22.30 %
EBITDA Margin (Avg.)
3.53 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 |
| Fixed Assets | 6,106 | 6,879 | 7,469 | 7,990 | 8,133 |
| Current Assets | 3,649 | 4,067 | 4,836 | 5,465 | 5,797 |
| Capital Work in Progress | 627 | 1,172 | 1,419 | 1,116 | 977 |
| Investments | 123 | 267 | 639 | 385 | 291 |
| Other Assets | 4,045 | 4,478 | 4,996 | 5,821 | 6,277 |
| Total Liabilities | 10,900 | 12,797 | 14,523 | 15,312 | 15,678 |
| Current Liabilities | 2,490 | 3,033 | 3,843 | 4,369 | 3,766 |
| Non Current Liabilities | 2,805 | 3,067 | 3,906 | 3,031 | 3,786 |
| Total Equity | 5,605 | 6,697 | 6,774 | 7,911 | 8,126 |
| Reserve & Surplus | 4,610 | 5,511 | 5,580 | 6,588 | 6,801 |
| Share Capital | 995 | 1,186 | 1,193 | 1,323 | 1,324 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 110 | -177 | -32 | 166 | -37 |
| Investing Activities | -4,464 | -1,737 | -1,334 | -416 | -488 |
| Operating Activities | 598 | 766 | 484 | 1,005 | 892 |
| Financing Activities | 3,977 | 794 | 818 | -422 | -441 |
Share Holding
| % Holding | Sept 2022 | Oct 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 34.79 % | 0.00 % | 34.79 % | 34.79 % | 34.79 % | 35.02 % | 35.02 % | 35.02 % | 35.02 % | 34.95 % | 34.95 % | 34.95 % | 34.95 % | 34.86 % |
| FIIs | 20.00 % | 0.00 % | 20.00 % | 20.00 % | 20.00 % | 18.04 % | 32.37 % | 32.51 % | 30.59 % | 31.42 % | 31.73 % | 31.68 % | 31.49 % | 30.86 % |
| DIIs | 4.86 % | 0.00 % | 5.28 % | 4.99 % | 5.49 % | 7.83 % | 8.02 % | 9.68 % | 12.12 % | 12.95 % | 13.81 % | 14.10 % | 14.78 % | 14.26 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 7.42 % | 0.00 % | 11.80 % | 13.94 % | 16.77 % | 16.81 % | 16.95 % | 15.57 % | 15.13 % | 13.94 % | 13.29 % | 13.29 % | 13.11 % | 14.07 % |
| Others | 32.92 % | 100.00 % | 28.14 % | 26.29 % | 22.95 % | 22.30 % | 7.64 % | 7.22 % | 7.14 % | 6.74 % | 6.22 % | 5.98 % | 5.66 % | 5.95 % |
| No of Share Holders | 1,79,957 | 1,79,948 | 2,29,960 | 2,41,359 | 2,77,270 | 2,95,773 | 2,97,225 | 2,92,312 | 2,97,996 | 3,06,398 | 3,59,751 | 4,18,442 | 4,32,843 | 4,58,430 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.00 | 0.11 | 0.14 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.00 | 0.05 | 0.07 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 02 Aug 2023 |  Rights | 5:46 | 02 Aug 2023 | 101.95 | 103.86 |
| 12 Jul 2024 |  Dividend | ₹ 0.11 /share | 12 Jul 2024 | 148.05 | 151.60 |
| 26 Jul 2024 |  Annual General Meeting | NA | 26 Jul 2024 | 157.10 | 166.30 |
| 23 Oct 2024 |  Quarterly Result Announcement | NA | 23 Oct 2024 | 221.30 | 215.15 |
| 28 Jan 2025 | Quarterly Result Announcement | NA | 28 Jan 2025 | 221.25 | 224.00 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 214.95 | 214.90 |
| 16 Jul 2025 | Dividend | ₹ 0.14 /share | 16 Jul 2025 | 214.90 | 216.22 |
| 28 Jul 2025 | Quarterly Result Announcement | NA | 28 Jul 2025 | 216.88 | 202.23 |
| 30 Jul 2025 | Annual General Meeting | NA | 30 Jul 2025 | 199.95 | 205.61 |
Announcements
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015
Sep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 02, 2025
Sep 02, 2025Sustainability Report - FY2024-25Aug 25, 2025
Aug 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 20, 2025
Aug 20, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Jul 31, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 30, 2025
Jul 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 29, 2025
Jul 29, 2025Unaudited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June 2025Jul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Jul 28, 2025Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited Held On 28Th July 2025Jul 28, 2025
Jul 28, 2025Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of Stock OptionsJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-RestructuringJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Credit RatingJul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Jul 18, 2025Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Jul 18, 2025
Jul 18, 2025Announcement Under Regulation 30 (LODR) - ESG RatingJul 10, 2025
Jul 10, 2025Company Update On LitigationJul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Jul 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 02, 2025
Jul 02, 2025Notice Of The 5Th Annual General Meeting (AGM) And Annual Report For The Financial Year 2024-25Jul 02, 2025
Jul 02, 2025Reg. 34 (1) Annual Report.Jul 02, 2025
Jul 02, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2025
Jun 26, 2025Corporate Action-Board to consider DividendJun 13, 2025
Jun 13, 2025Intimation Of Record Date For Payment Of Final DividendJun 13, 2025
Jun 13, 2025Intimation Of 5Th Annual General Meeting To Be Held On Wednesday July 30 2025Jun 13, 2025
Jun 13, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)Jun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 02, 2025
Jun 02, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
May 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
May 14, 2025Audited Financial Results (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St March 2025May 14, 2025
May 14, 2025Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 14Th
May 2025May 14, 2025
May 14, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Capacity Expansion Of Lexington And Riverview SitesMay 12, 2025
May 12, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At TurbheMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Apr 29, 2025Technical Indicators
RSI(14)
Neutral 37.00
ATR(14)
Volatile 5.36
STOCH(9,6)
Neutral 24.84
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -1.25
ADX(14)
Weak Trend 19.51
UO(9)
Bearish 30.01
ROC(12)
Downtrend And Accelerating -5.76
WillR(14)
Oversold -96.75
Mutual Fund Holdings
Kotak Arbitrage Fund Direct-Growth 
HDFC Focused Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
Canara Robeco Balanced Advantage Fund Direct - Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
LIC MF Small Cap Fund Direct - Growth 
ICICI Prudential Children's Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
Nippon India Arbitrage Fund Direct-Growth 
Axis Nifty Smallcap 50 Index Fund Direct-Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth About Piramal Pharma
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics (CHG) business, and an India Consumer Healthcare (ICH) business. Piramal Pharma Solutions provides integrated drug discovery, development, and manufacturing services. The company has a joint venture with Allergan in ophthalmology and a minority investment in Yapan Bio for biologics and vaccines. It is a leading player in India's self-care space with established brands. The company specializes in niche areas such as highly potent APIs, antibody drug conjugates, and biologics. In 2022, Piramal Pharma Limited was listed on the BSE and NSE following a demerger from Piramal Enterprises Limited.
Chairperson NameNandini Piramal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
